Lipum patent granted in Canada

Lipum AB is the assignee of a strong patent portfolio and the rights of the patent from the inventors and the results within the BSSL research have all been transferred to the company. The patent "New method for treatment of inflammatory diseases.", previously granted on most major markets, has now also been approved in Canada. [...]

2017-11-02T11:06:28+00:00

Lipum presenting at Anglonordic, London, May 31

We will present our recent advancements in the development of a biological drug for treatment of chronic inflammatory diseases. Pre-clinical results based on well established models have shown the importance of our novel target molecule, the bile-salt stimulated lipase (BSSL). The development of a humanised antibody is in progress and Lipum is actively seeking partners [...]

2017-11-02T11:01:22+00:00